HC Wainwright Has Negative Estimate for BHST FY2028 Earnings

BioHarvest Sciences Inc. (NASDAQ:BHST) – Investment analysts at HC Wainwright decreased their FY2028 earnings per share estimates for shares of BioHarvest Sciences in a report released on Friday, May 15th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings of $0.26 per share for the year, down from their previous estimate of $0.36. The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ FY2030 earnings at $1.50 EPS.

BioHarvest Sciences (NASDAQ:BHST) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. BioHarvest Sciences had a negative return on equity of 76.03% and a negative net margin of 32.54%.The business had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $8.50 million.

Other analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Friday, March 27th. Roth Mkm began coverage on BioHarvest Sciences in a report on Thursday, February 19th. They set a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

BioHarvest Sciences Price Performance

Shares of NASDAQ:BHST opened at $3.92 on Monday. BioHarvest Sciences has a 1-year low of $3.57 and a 1-year high of $12.80. The firm has a market capitalization of $76.91 million, a PE ratio of -6.64 and a beta of 0.81. The business’s 50 day moving average is $4.25 and its 200-day moving average is $5.17. The company has a current ratio of 2.96, a quick ratio of 3.38 and a debt-to-equity ratio of 0.03.

Institutional Investors Weigh In On BioHarvest Sciences

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in BioHarvest Sciences during the 4th quarter worth approximately $60,000. Geode Capital Management LLC bought a new stake in BioHarvest Sciences during the 4th quarter worth approximately $61,000. HRT Financial LP bought a new stake in BioHarvest Sciences during the 4th quarter worth approximately $75,000. Marshall Wace LLP bought a new stake in BioHarvest Sciences during the 4th quarter worth approximately $110,000. Finally, Silverberg Bernstein Capital Management LLC bought a new stake in BioHarvest Sciences during the 1st quarter worth approximately $113,000.

BioHarvest Sciences News Roundup

Here are the key news stories impacting BioHarvest Sciences this week:

• Positive Sentiment: BioHarvest expanded its collaboration with Tate & Lyle to broaden the joint sweetener development program to include multiple plant-based sweetener molecules, which could strengthen its commercial pipeline and validate its Botanical Synthesis platform. BioHarvest Sciences and Tate & Lyle expand sweetener development program
• Positive Sentiment: The Tate & Lyle partnership expansion was also confirmed in a company release, reinforcing the strategic nature of the relationship and the potential for future product development in food and beverage sweeteners. Tate & Lyle Expands Collaboration with BioHarvest Sciences to Accelerate Next-Generation Sweetener Innovation
• Neutral Sentiment: HC Wainwright lowered near-term EPS estimates for BioHarvest Sciences for Q2, Q3, Q4, and FY2026, and also cut FY2027 estimates, which likely weighs on sentiment by signaling slower profitability progress than previously expected.
• Neutral Sentiment: The same analyst raised FY2029 EPS estimates, suggesting longer-term expectations remain intact even as the near-term outlook is weaker.
• Neutral Sentiment: BioHarvest’s Q1 2026 earnings transcript was also published, but no new headline catalyst beyond the recently reported results appears to be driving the stock.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.